Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myr-Tat-PKCβII inhibitor
- Development stage
- Preclinical
- Lead developer
- Philadelphia College of Osteopathic Medicine
- Modality
- Peptides
- Administration
- Intraperitoneal
01
Overview
Myr-Tat-PKCβII inhibitor is a cell-permeable research peptide designed to selectively inhibit protein kinase C beta II (PKCβII). The peptide sequence (N-myr-Tat-CC-SLNPEWNET) is dual-conjugated to myristic acid for membrane anchoring and the Trans-activator of transcription (TAT) sequence for cellular internalization. Its primary mechanism involves blocking the PKCβII-mediated phosphorylation of NADPH oxidase (NOX-2) subunits, thereby attenuating the production of superoxide by polymorphonuclear (PMN) cells. Research has demonstrated its potential in reducing myocardial ischemia/reperfusion injury and decreasing the viability of estrogen receptor-positive (ER+) breast cancer cells (MCF-7) by disrupting estrogen-driven growth pathways. It is primarily utilized as a laboratory tool in academic research.
- Other names
- cell-permeable PKCβII peptide inhibitormyristoylated PKCβII peptide inhibitor
02
Targets
RACK1 (Receptor for activated C kinase 1)
Beyond the preview
Go deeper on Myr-Tat-PKCβII inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myr-Tat-PKCβII inhibitor.